Charitable Foundation. AlCana is currently concluding an agreement with a charitable foundation (“Foundation”) covering a research and development program. The name of the Foundation will be disclosed in the detailed agreement. The planned research is directed at development of potential therapeutics for the treatment of a specific chronic and currently untreatable disease (“Foundation Disease”) [**]. The research program will include studies involving potential RNAi therapeutics. Tekmira agrees that AlCana will undertake this program under the following conditions:
Appears in 2 contracts
Samples: Settlement Agreement and General Release (TEKMIRA PHARMACEUTICALS Corp), Settlement Agreement and General Release (Alnylam Pharmaceuticals, Inc.)
Charitable Foundation. AlCana is currently concluding an agreement with a charitable foundation (“Foundation”) covering a research and development program. The name of the Foundation will be disclosed in the detailed agreement. The planned research is directed at development of potential therapeutics for the treatment of a specific chronic and currently untreatable disease (“Foundation Disease”) [**Redacted – Research Field]. The research program will include studies involving potential RNAi therapeutics. Tekmira agrees that AlCana will undertake this program under the following conditions:
Appears in 2 contracts
Samples: Settlement Agreement and General Release, Settlement Agreement and General Release (TEKMIRA PHARMACEUTICALS Corp)
